Inovio Pharmaceuticals posts $21.2 million operating loss for Q3 2025

Reuters

2025/11/11

Inovio Pharmaceuticals posts $21.2 million operating loss for Q3 2025

Inovio Pharmaceuticals Inc. reported a loss from operations of $21.2 million, or $0.41 per share, for the quarter ended September 30, 2025, compared to a loss of $27.3 million, or $0.97 per share, for the same quarter in 2024. As of September 30, 2025, Inovio held $50.8 million in cash, cash equivalents, and short-term investments, down from $94.1 million at the end of 2024. The company had 53.6 million common shares outstanding, with 94.5 million on a fully diluted basis. Inovio estimates its current cash resources will support operations into the second quarter of 2026. Key business developments include the completion of a rolling Biologics License Application submission for INO-3107, with priority review requested and potential FDA approval and launch targeted for mid-2026. Results from a Phase 1 trial of Inovio's DNA-Encoded Monoclonal Antibody technology were published in Nature Medicine.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inovio Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: PH20551) on November 10, 2025, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2582800325"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2582800325\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2582800325?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-11 05:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2582800325","market":"us","top_or_hot":-1,"title":"Inovio Pharmaceuticals posts $21.2 million operating loss for Q3 2025","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Inovio Pharmaceuticals posts $21.2 million operating loss for Q3 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Inovio Pharmaceuticals Inc. reported a loss from operations of $21.2 million, or $0.41 per share, for the quarter ended September 30, 2025, compared to a loss of $27.3 million, or $0.97 per share, for the same quarter in 2024. As of September 30, 2025, Inovio held $50.8 million in cash, cash equivalents, and short-term investments, down from $94.1 million at the end of 2024. The company had 53.6 million common shares outstanding, with 94.5 million on a fully diluted basis. Inovio estimates its current cash resources will support operations into the second quarter of 2026. Key business developments include the completion of a rolling Biologics License Application submission for INO-3107, with priority review requested and potential FDA approval and launch targeted for mid-2026. Results from a Phase 1 trial of Inovio's DNA-Encoded Monoclonal Antibody technology were published in Nature Medicine.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inovio Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: PH20551) on November 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Inovio Pharmaceuticals posts $21.2 million operating loss for Q3 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInovio Pharmaceuticals posts $21.2 million operating loss for Q3 2025\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-11-11 05:07</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Inovio Pharmaceuticals posts $21.2 million operating loss for Q3 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Inovio Pharmaceuticals Inc. reported a loss from operations of $21.2 million, or $0.41 per share, for the quarter ended September 30, 2025, compared to a loss of $27.3 million, or $0.97 per share, for the same quarter in 2024. As of September 30, 2025, Inovio held $50.8 million in cash, cash equivalents, and short-term investments, down from $94.1 million at the end of 2024. The company had 53.6 million common shares outstanding, with 94.5 million on a fully diluted basis. Inovio estimates its current cash resources will support operations into the second quarter of 2026. Key business developments include the completion of a rolling Biologics License Application submission for INO-3107, with priority review requested and potential FDA approval and launch targeted for mid-2026. Results from a Phase 1 trial of Inovio's DNA-Encoded Monoclonal Antibody technology were published in Nature Medicine.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inovio Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: PH20551) on November 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4583","symbol_name":"猴痘概念","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nNDL7hpRzj:1","article_id":"2582800325","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2582800325","pubTimestamp":1762808874,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Inovio Pharmaceuticals Inc. reported a loss from operations of $21.2 million, or $0.41 per share, for the quarter ended September 30, 2025, compared to a loss of $27.3 million, or $0.97 per share, for the same quarter in 2024. As of September 30, 2025, Inovio held $50.8 million in cash, cash equivalents, and short-term investments, down from $94.1 million at the end of 2024. The company had 53.6 million common shares outstanding, with 94.5 million on a fully diluted basis. Inovio estimates its current cash resources will support operations into the second quarter of 2026. Key business developments include the completion of a rolling Biologics License Application submission for INO-3107, with priority review requested and potential FDA approval and launch targeted for mid-2026. Results from a Phase 1 trial of Inovio's DNA-Encoded Monoclonal Antibody technology were published in Nature Medicine.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4583":"猴痘概念","BK4139":"生物科技","INO":"伊诺维奥制药","BK4568":"美国抗疫概念"},"translate_title":"Inovio Pharmaceuticals公布2025年第三季度运营亏损2120万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INO":0.9},"content_text":"Inovio Pharmaceuticals posts $21.2 million operating loss for Q3 2025\n    \n\n        Inovio Pharmaceuticals Inc. reported a loss from operations of $21.2 million, or $0.41 per share, for the quarter ended September 30, 2025, compared to a loss of $27.3 million, or $0.97 per share, for the same quarter in 2024. As of September 30, 2025, Inovio held $50.8 million in cash, cash equivalents, and short-term investments, down from $94.1 million at the end of 2024. The company had 53.6 million common shares outstanding, with 94.5 million on a fully diluted basis. Inovio estimates its current cash resources will support operations into the second quarter of 2026. Key business developments include the completion of a rolling Biologics License Application submission for INO-3107, with priority review requested and potential FDA approval and launch targeted for mid-2026. Results from a Phase 1 trial of Inovio's DNA-Encoded Monoclonal Antibody technology were published in Nature Medicine.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inovio Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: PH20551) on November 10, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}